These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32331242)

  • 1. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
    Franssen LE; Stege CAM; Zweegman S; van de Donk NWCJ; Nijhof IS
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
    van de Donk NWCJ
    Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
    Shah B; Gray J; Abraham I; Chang M
    J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 10. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
    Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
    Front Immunol; 2020; 11():1771. PubMed ID: 32922390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
    Morè S; Petrucci MT; Corvatta L; Fazio F; Offidani M; Olivieri A
    Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33260960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
    Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
    Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
    De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
    Moreno L; Perez C; Zabaleta A; Manrique I; Alignani D; Ajona D; Blanco L; Lasa M; Maiso P; Rodriguez I; Garate S; Jelinek T; Segura V; Moreno C; Merino J; Rodriguez-Otero P; Panizo C; Prosper F; San-Miguel JF; Paiva B
    Clin Cancer Res; 2019 May; 25(10):3176-3187. PubMed ID: 30692097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
    Leleu X; Martin T; Weisel K; Schjesvold F; Iida S; Malavasi F; Manier S; Chang-Ki Min ; Ocio EM; Pawlyn C; Perrot A; Quach H; Richter J; Spicka I; Yong K; Richardson PG
    Ann Hematol; 2022 Oct; 101(10):2123-2137. PubMed ID: 35943588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
    Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
    Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.